Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults

Viral vectored vaccines using chimpanzee adenoviruses and Modified Vaccinia Ankara (MVA) vectors have demonstrated efficacy against Ebolavirus challenge in non-human primates. This Phase 1 trial was designed to assess the safety and immunogenicity of 2 novel Ebolavirus vaccines in healthy UK adults: the monovalent chimpanzee adenovirus 3 vector encoding Zaire Ebolavirus glycoprotein (ChAd3-EBO Z) and the multivalent MVA encoding multiple filoviral proteins (MVA-BN® Filo).